Follow
Sylvie Guichard
Sylvie Guichard
Director Translational Science Forma Therapeutics
Verified email at astrazeneca.com
Title
Cited by
Cited by
Year
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ...
autophagy 17 (1), 1-382, 2021
11195*2021
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity
CM Chresta, BR Davies, I Hickson, T Harding, S Cosulich, SE Critchlow, ...
Cancer research 70 (1), 288-298, 2010
8082010
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT SignalingmTOR Kinase Inhibition Has Opposing Effects on AKT
VS Rodrik-Outmezguine, S Chandarlapaty, NC Pagano, PI Poulikakos, ...
Cancer discovery 1 (3), 248-259, 2011
4662011
Controlling ligand substitution reactions of organometallic complexes: Tuning cancer cell cytotoxicity
F Wang, A Habtemariam, EPL van der Geer, R Fernández, M Melchart, ...
Proceedings of the National Academy of Sciences 102 (51), 18269-18274, 2005
3142005
Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells
P Casado, JC Rodriguez-Prados, SC Cosulich, S Guichard, ...
Science signaling 6 (268), rs6-rs6, 2013
2462013
Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines
S Arnould, I Hennebelle, P Canal, R Bugat, S Guichard
European journal of cancer 39 (1), 112-119, 2003
2122003
Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein …
KM Foote, K Blades, A Cronin, S Fillery, SS Guichard, L Hassall, I Hickson, ...
Journal of medicinal chemistry 56 (5), 2125-2138, 2013
2082013
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
L Willems, N Chapuis, A Puissant, TT Maciel, AS Green, N Jacque, ...
Leukemia 26 (6), 1195-1202, 2012
1682012
CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues
S Guichard, C Terret, I Hennebelle, I Lochon, P Chevreau, E Fretigny, ...
British journal of cancer 80 (3), 364-370, 1999
1671999
Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors
EM Sommer, H Dry, D Cross, S Guichard, BR Davies, DR Alessi
Biochemical Journal 452 (3), 499-508, 2013
1642013
Aspirin activates the NF-κB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer
LA Stark, K Reid, OJ Sansom, FV Din, S Guichard, I Mayer, DI Jodrell, ...
Carcinogenesis 28 (5), 968-976, 2007
1522007
Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent
KM Foote, JWM Nissink, T McGuire, P Turner, S Guichard, JWT Yates, ...
Journal of Medicinal Chemistry 61 (22), 9889-9907, 2018
1422018
Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line
S Guichard, I Hennebelle, R Bugat, P Canal
Biochemical pharmacology 55 (5), 667-676, 1998
1221998
Practical treatment guide for dose individualisation in cancer chemotherapy
P Canal, E Chatelut, S Guichard
Drugs 56 (6), 1019-1038, 1998
1181998
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous SchedulesPharmacology of AZD2014, an …
SM Guichard, J Curwen, T Bihani, CM D'Cruz, JWT Yates, M Grondine, ...
Molecular cancer therapeutics 14 (11), 2508-2518, 2015
1142015
Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells
P Sini, D James, C Chresta, S Guichard
Autophagy 6 (4), 553-554, 2010
1032010
Structure−Activity Relationships of Monomeric C2-Aryl Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Antitumor Agents
D Antonow, M Kaliszczak, GD Kang, M Coffils, AC Tiberghien, N Cooper, ...
Journal of medicinal chemistry 53 (7), 2927-2941, 2010
1022010
Sequence‐dependent activity of the irinotecan‐5FU combination in human colon‐cancer model HT‐29 in vitro and in vivo
S Guichard, D Cussac, I Hennebelle, R Bugat, P Canal
International journal of cancer 73 (5), 729-734, 1997
1001997
Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055) Preclinical Combinations of Selumetinib and …
SV Holt, A Logie, BR Davies, D Alferez, S Runswick, S Fenton, ...
Cancer research 72 (7), 1804-1813, 2012
922012
Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium (II) based organo-metallic compounds
SM Guichard, R Else, E Reid, B Zeitlin, R Aird, M Muir, M Dodds, H Fiebig, ...
Biochemical pharmacology 71 (4), 408-415, 2006
922006
The system can't perform the operation now. Try again later.
Articles 1–20